Home » Archive by Category


San Diego biotech news from BioSpace, Xconomy, PR Newswire, Marketwired and other sources, click on headlines to read the full story.

ResMed Inc. Launches Data Exchange

October 20, 2014 – 5:00 am | Edit Post

SAN DIEGO, Oct. 20, 2014 /PRNewswire/ –ResMed (NYSE:RMD) today announced the availability of the ResMed Data Exchange program, a comprehensive suite of software and service solutions for home medical equipment (HME) and other health care providers. ResMed Data Exchange offers timely, secure access to…

VG Life Sciences, Inc. Release: New Data Implicate Components Of Adaptive Immunity In Traumatic Brain Injury

October 20, 2014 – 5:00 am | Edit Post

SANTA BARBARA, Calif., Oct. 20, 2014 (GLOBE NEWSWIRE) — VG Life Sciences Inc., (OTCQB:VGLS) a biotechnology company, announces today that one of its scientific advisors, Dr. Richard Tobin, PhD, published data demonstrating that when there is traumatic brain injury (TBI), the body inflicts additional…

Genervon Announces ALS And PD Phase 2a Trial Results

October 20, 2014 – 5:00 am | Edit Post

PASADENA, Calif.–(BUSINESS WIRE)–Genervon Biopharmaceuticals LLC (Genervon) today announced that it has completed the analysis of its Phase 2a double blinded, randomized, placebo controlled clinical trials of Amyotrophic Lateral Sclerosis (ALS)(NCT01854294) and Parkinsons disease (PD)(NCT 01850381) for its drug candidate GM6 (also known as GM604 in the ALS trial and GM608 in the PD trial…

AnaptysBio, Inc. Appoints To Newly Created Chief Development Officer Position Clinical Immunologist To Lead s Pipeline Advancement

October 20, 2014 – 5:00 am | Edit Post

SAN DIEGO, Oct. 20, 2014 /PRNewswire/ –AnaptysBio, Inc., a leader in the discovery and development of therapeutic antibodies, today announced the appointment of Marco Londei, M.D. as Chief Development Officer. Dr. Londei will lead the preclinical and clinical development of AnaptysBio…

Personalis Introduces New Services For Cancer Research And Clinical Trials

October 20, 2014 – 5:00 am | Edit Post

Personalis, Inc., a leading genomics-based service provider, today announced it is launching an expanded portfolio of cancer research solutions based on its ACE (Accuracy and Content Enhanced) sequencing, informatics and content technology platform. Scientists from Personalis presented the new portfolio of cancer research solutions this weekend to attendees at the 2014 American Society of Human Genetics…

BioNano Genomics Announces One Human : One Chip : One Day

October 20, 2014 – 5:00 am | Edit Post

SAN DIEGO, Oct. 20, 2014 /PRNewswire/ –BioNano Genomics announced today achievement of a major milestone for the Irys system: the ability to collect human data at 30X depth, sufficient for a genome map, in 24 hours on a single chip…

Epic Sciences Appoints As Chief Information Officer

October 20, 2014 – 5:00 am | Edit Post

SAN DIEGO, Oct. 20, 2014 /PRNewswire/ –Epic Sciences announced today the appointment of Michael Giskeas chief information officer. Mr. Giske has more than 25 years of defining, designing and implementing…

Pathway Genomics Corporation Launches Patient Mobile App At American Society of Human Genetics 2014

October 20, 2014 – 5:00 am | Edit Post

Pathway Genomics Corporation, a CLIA and CAP accredited clinical laboratory that offers genetic testing services globally, announced it has released a patient app that allows existing patients to view their genetic results on mobile devices, such as smart phones and tablets. The announcement was made at the 64th Annual Meeting of the American Society of Human Genetics (ASHG) in San Diego, California…

Cypher Genomics Identifies And Verifies Genetic Cause Of Rare Disease, Epileptic Encephalopathy

October 20, 2014 – 5:00 am | Edit Post

SAN DIEGO, Oct. 20, 2014 /PRNewswire/ –Cypher Genomics, Inc., the genome informatics company, announced today the identification of de novoKCNB1 missense mutations as a novel genetic cause of severe epileptic encephalopathy…

Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs

October 20, 2014 – 5:00 am | Edit Post

SAN DIEGO, Oct. 20, 2014 /PRNewswire/ — Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, received official notification from the European Patent Office that the company has been granted another key patent supporting its iSONEP™ and ASONEP™ programs.

This newly issued patent, European patent No. 2087002, claims compositions of matter related to sonepcizumab, the drug substance in Lpath’s two lead compounds, iSONEP and ASONEP. Sonepcizumab is an antibody that binds to and inhibits sphingosine-1-phosphate (S1P), a bioactive lipid that has been validated as a target in multiple disease states.

Specifically, this patent claims antibody compositions and nucleic acids encoding heavy and light chains of antibodies and antibody fragments to S1P, as well as engineered plasmids and host cells designed to express a humanized monoclonal antibody to S1P. Utility claims are also granted for using anti-S1P antibodies to treat neovascularization, angiogenesis, endothelial-cell proliferation, and fibrogenesis.

iSONEP (formulated for ocular administration) and ASONEP (formulated for systemic administration) are different formulations of a first-in-class therapeutic antibody developed by Lpath’s ImmuneY2™ drug-discovery engine. Antibodies developed via this discovery engine are designed to bind and neutralize bioactive signaling lipids, such as S1P, that are involved in the proliferation and spread of cancer, age-related macular degeneration (AMD),  inflammatory and auto-immune disorders, and many other diseases.

“This patent provides key coverage in Europe for use of our anti-S1P antibodies and complements our other recently issued patents in the U.S. as well as patent claims we have been granted in Europe for wet AMD, cancer, and other conditions,” said Roger Sabbadini, Lpath’s vice president, founder, and an inventor of the issued patent.

Lpath is conducting a double-blind, four-arm Phase 2 clinical trial (the “Nexus” trial), which is evaluating iSONEP’s safety and efficacy in wet-AMD patients that have not responded well to existing anti-VEGF therapies (Lucentis®, Avastin® and Eylea®). Lpath entered into an agreement with Pfizer in 2010 that provides Pfizer an exclusive option for a worldwide license to develop and commercialize iSONEP.

Additionally, Lpath is conducting a Phase 2a trial in renal cell carcinoma patients with ASONEP; results thus far have been encouraging and suggest that additional efficacy studies—in renal cell carcinoma and/or other tumor types—are warranted.

About Lpath San Diego-based Lpath, Inc. (NASDAQ: LPTN), an antibody-platform company, is the category leader in lipid-targeted therapeutics. The company’s ImmuneY2™ drug-discovery engine has the unique ability to generate therapeutic antibodies that bind to and inhibit bioactive lipids that contribute to disease. The company has developed four drug candidates, two of which—iSONEP for wet AMD and ASONEP for cancer—are currently being investigated in Phase 2 trials. The other candidates are an anti-LPA antibody, Lpathomab, a soon-to-be Phase 1 compound for neuropathic pain and neurotrauma and an anti-leukotriene antibody, Altepan, which is being studied in models of respiratory disease and inflammation. For more information, visit www.Lpath.com.

About Forward-Looking StatementsThe Company cautions you that the statements included in this press release that are not a description of historical facts are forward-looking statements. These include statements regarding: the protection against competition afforded by issued patents; the eventual commercial viability of the Company’s drug programs; and the Company’s ability to complete additional discovery and development activities for drug candidates utilizing its proprietary ImmuneY2 drug-discovery process. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in the Company’s business, including, without limitation: the results of the Company’s preclinical studies and clinical trials may not support further clinical development and/or the commercialization of its drug candidates; the Company may not successfully complete additional clinical trials for its product candidates on a timely basis, or at all; the Company may fail to obtain required governmental approvals for any of its drug candidates; the Company may not be successful in maintaining its commercial relationship with Pfizer Inc. or any third party that acquires Pfizer’s exclusive option to iSONEP; and the Company may not be able to secure the funds necessary to support its preclinical-development and clinical-development plans. More detailed information about the risk factors and uncertainties that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (the “SEC”), including its Annual Report on Form 10-K, its Quarterly Reports on Form 10-Q, and its other filings with the SEC. Such documents may be read free of charge on the SEC’s website at www.sec.gov. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and the Company undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.
SOURCE Lpath, Inc.